Clinical Trial

Efficacy of Co-Spinal Ondansetron In Inguinal Herniorrhaphy

Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated April 30, 2025 (before its estimated June 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
Ondansetron, a selective serotonin 5-HT3 receptor antagonist, is well known for its antiemetic effects. However, its ability to reduce hypotension during spinal anesthesia has recently sparked great interest. In clinical practice, administering ondansetron before spinal anesthesia has produced promising results.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-22.
Status change: Not Yet Recruiting → Enrolling by Invitation 2025-04-26
Trial Details
NCT Number NCT06850740
Lead Sponsor Suez Canal University
Conditions Hernia, Inguinal
Enrollment 46 participants
Start Date 2025-03-15
Primary Completion 2025-06-15 (estimated)
Study Completion 2025-08-15 (estimated)
Updated on ClinicalTrials.gov 2025-04-30